Ono Pharmaceutical Co., Ltd. · TSE:4528

Ono Pharmaceutical — ESG Presentation (March 2025)

34 slides from Ono Pharmaceutical's sustainability presentation, Mar 5, 2025

  1. Slide 1: Sustainability Meeting

    Sustainability Meeting March 5, 2025

  2. Slide 2: Cautionary Notes

    Cautionary Notes Forecasts and other forward-looking statements included in this document are based on information currently available and certain assumptions that the Company deems reasonable. Actual performance and other results may differ significantly due to various factors. Such factors include

  3. Slide 3: Agenda

    Agenda Materiality Updates(13:00-13:15) Representative Director, President and Chief Operating Officer Toichi Takino Promotion of Diversity(13:15-13:25) Member of the Board of Directors, Outside Director Akiko Okuno ESG Initiatives to Promote Growth Strategies(13:25-13:45) Representative Director, E

  4. Slide 4: Materiality Updates

    Materiality Updates 4 / 33

  5. Slide 5: Reorganize Business Operations in the US and Europe to Accelerate Global Expansion

    Reorganize Business Operations in the US and Europe to Accelerate Global Expansion Consolidating ONO Group's US and Europe business functions into Deciphera to realize growth toward becoming a global specialty pharmaceutical company Main functions to be consolidated ・Development and sales functions

  6. Slide 6: Materiality Updates

    Materiality Updates With the acquisition of Deciphera and the establishment of the direct sales system in the US and Europe, we have revised our materiality. Incorporating the opinions of external stakeholders, we consolidated 18 materialities into 9, clarifying our focus and priorities. 6 / 33

  7. Slide 7: Materiality (Growth Strategy)

    Materiality (Growth Strategy) Growth Strategy 1 Strengthening Our Pipeline 2 Acceleration of Global Business Advancement Maximization of 3 4 Expansion of Business Domains Product Value Vision over the medium- to long-term • Collaborate with top scientists to accelerate drug discovery for changing th

  8. Slide 8: Materiality (Foundation for Promoting Growth Strategies, Realization of a Sustainable Society)

    Materiality(Foundation for Promoting Growth Strategies, Realization of a Sustainable Society) Foundation for Promoting the Growth Strategy 5 Corporate Transformation through 6 Expansion of Human Capital Digital & IT Vision over the medium- to long-term 5 • A secured global IT infrastructure is being

  9. Slide 9: New Materiality

    New Materiality Under our sustainable management policy, we are committed to growth strategies, expanding key foundations, and realizing a sustainable society. By contributing to people's health, we aim to achieve sustainable growth for both society and our company. Growth Strategy Realization of a

  10. Slide 10: Promotion of Diversity

    Promotion of Diversity 10 / 33

  11. Slide 11: Management List

    Management List Name Positions, Responsibilities and Significant Concurrent Positions Gyo Sagara Representative Director, Chairman of the Board and Chief Executive Officer Internal Toichi Takino Representative Director, President and Chief Operating Officer (3) Representative Director, Executive Vic

  12. Slide 12: Current Challenges

    Current Challenges Approach to tackle the OPDIVO Patent Cliff Global expansion, Pipeline expansion ⇒ Accelerate global expansion through the acquisition of Deciphera Issues from the perspective of outside directors “Adapting to change” (Especially in HR policies) 12 / 33

  13. Slide 13: What is Needed for "Change"

    What is Needed for “Change” First global M&A for Ono Pharmaceutical Task differences: Technical problems ⇒ Adapt effectively Cultural differences: Social and corporate culture (people-related issues) ⇒ Understanding and Leveraging Diversity Need to share/empathize The Group's Common Values (Corporat

  14. Slide 14: Initiatives to Improve Diversity and Enhance Engagement

    Initiatives to Improve Diversity and Enhance Engagement Fairness and Transparency Establish a global HR system, promote the active participation of women and mid-career hires Expression of individuality Systems for open internal job posting & "Challenge jobs"* etc. * Exploring new opportunities by t

  15. Slide 15: Next Steps

    Next Steps Promote active careers for women • The harsh current reality: (Percentage of female managers: Currently 7.3%, target for FY2026: 10% / target for FY2031: 20%) • We are making steady, consistent effort. Although there has been no rapid progress, the organization's culture is beginning to c

  16. Slide 16: ESG Initiatives to Promote Growth Strategies

    ESG Initiatives to Promote Growth Strategies 16 / 33

  17. Slide 17: Strengthening the management infrastructures

    Strengthening the management infrastructures Management infrastructures to support growth strategies - Expansion of intangible assets -  Digital & IT • Challenge toward DX • Implementation of globally standardized and flexible IT infrastructure  Expansion of human capital  Corporate branding • De

  18. Slide 18: Changes in the ratio of female managers based on the current status and promotion plan

    Changes in the ratio of female managers based on the current status and promotion plan  The goals at FY 2026 will be achieved, but the goals at FY 2031 are not expected to be achieved.  We need more active promotion of development plans and recruitment, especially of personnel who can serve as rol

  19. Slide 19: Roadmap for recruitment, development, and promotion of female managers

    Roadmap for recruitment, development, and promotion of female managers Promotion to management Learning, mindset and growth GROW Interacting with other Internal Mentoring Program company employees This program encourages female This training helps female colleagues In this program, female employees

  20. Slide 20: Human resource strategy to expand human capital

    Human resource strategy to expand human capital Strengthening Acceleration of Global Expansion of Maximization of Specialized Product Value Our Pipeline Business Business Advancement Domains human resources Cross-Sectional HumanResources 20 / 33

  21. Slide 21: [Reference] Examples of development of specialized human resources in each division

    [Reference] Examples of development of specialized human resources in each division Headquarters Human Resources Requirements Training content After M & A, deal with consolidated financial statements and PMI in the We will work with FA to develop an Corporate Strategy Finance area integrated account

  22. Slide 22: Results of Survey on Specialized Human Resources (Overall Summary)

    Results of Survey on Specialized Human Resources (Overall Summary) ■Promoted career recruitment and development to graduate training candidates the required number of 706 (as of 25/2) Approximately 1.5 employees /position selected 800 695 subjects 706 subjects required to be adopted ① Maximize produ

  23. Slide 23: Progress of specialized human resources by the end of FY2026 (forecast)

    Progress of specialized human resources by the end of FY 2026 (forecast) Estimated progress (cumulative value) 900 848 800 necessary for development (706 people) 700 414 600 520 500 127  As shown in the left figure, by FY 2026, 400 353 81 40 Specialized human resources exceeding 300 64 64 64 the re

  24. Slide 24: Engagement Survey Results (FY 2023)

    Engagement Survey Results (FY 2023) • Engagement is at a high level compared to benchmarks of all domestic Points industries while increasing the response rate. (Slightly below the benchmark of global life sciences) • The engagement score increased by one point compared to last year. Survey period S

  25. Slide 25: Engagement and Mission Statement

    Engagement and Mission Statement 5 most positive responses I sympathize with Mission Statement of the company The management encourages the employees to escalate important information to the supervisors even if it is bad news. My direct supervisor treats me with respect and dignity. I myself want to

  26. Slide 26: ONO's Mission Statement

    ONO’s Mission Statement Corporate Philosophy Dedicated to the Fight against Disease and Pain Our Vision Be Passionate Challengers Our Vision is to strive with the utmost effort and strong determination to meet the challenge of combining our individual competencies to deliver new, innovative drugs to

  27. Slide 27: What is required to accomplish our mission

    What is required to accomplish our mission There are things that ONO Group has valued, and there are things that Deciphera has valued. By learning about and connecting with each other’s values, we can achieve mutual understanding. Mutual understanding 相互理解 ONO Group Deciphera Corporate Philosophy On

  28. Slide 28: Measures to disseminate Mission Statement

    Measures to disseminate Mission Statement Implementation of measures from the top Enhancement of communication Effectively communicate the Mission Statement to all employees Town hall meeting Implementation of measures at each workplace Implementation of measures by HR Encouragement of Education an

  29. Slide 29: Lastly...

    Lastly... Let’s make the ONO Mission Statement our common language and use it to facilitate communication across countries, regions, and divisions, deepening mutual understanding and foster a sense of unity. 29 / 33

  30. Slide 30: What is ONO Sustainability?

    What is ONO Sustainability? [Policy for the next 100 years] We contribute to the sustainable development of society through our business. In addition to contributing to people's health through our core business, we will continue to take on the challenge of realizing a sustainable society under the p

  31. Slide 31: External evaluation of ESG in FY 2024

    External evaluation of ESG in FY 2024 Rating Agency Evaluation Content Number of Selections Pharma DJSI World Index 5 consecutive years Sector Dow Jones Sustainability Index DJSI Asia Pacific Index 5 consecutive years Selected for operation start MSCI NIHONKABU ESG Select Leaders Index in 2024 MSCI

  32. Slide 32: Initiatives on Biodiversity

    Initiatives on Biodiversity Minimizing the negative impact on the nature, contribute to the realization of Nature Positive* by 2030 A first for a pharmaceutical company In August 2024, disclosure will be in line with the recommendations of the Task Force on Nature-related Financial Disclosures (TNFD

  33. Slide 33: Enhancing Corporate Value Through Sustainability

    Enhancing Corporate Value Through Sustainability Requests from society Sustainable growth Environment Governance Solving social Social and Contribution environmental Activity issues Drug creation Product value Maximize Corporate growth Individual Employee Activities Our company aims to enhance corpo

  34. Slide 34: Dedicated to the Fight against Disease and Pain

    Dedicated to the Fight against Disease and Pain

Ono Pharmaceutical — ESG Presentation (March 2025) on 6ix